Cargando…
Somatostatin-based radiotherapy with [(90)Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
BACKGROUND: We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [(90)Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors. METHODS: In a clinical phase I dose escalation study we treated patients with increasing...
Autores principales: | Marincek, Nicolas, Jörg, Ann-Catherine, Brunner, Philippe, Schindler, Christian, Koller, Michael T, Rochlitz, Christoph, Müller-Brand, Jan, Maecke, Helmut R, Briel, Matthias, Walter, Martin A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3561188/ https://www.ncbi.nlm.nih.gov/pubmed/23320604 http://dx.doi.org/10.1186/1479-5876-11-17 |
Ejemplares similares
-
Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [(64)Cu]Cu-DOTA-TOC
por: Vahidfar, Nasim, et al.
Publicado: (2022) -
Impact of segmentation and discretization on radiomic features in (68)Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
por: Liberini, Virginia, et al.
Publicado: (2021) -
Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021) -
The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018) -
Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)